Download video

Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?

139 views

VJHemOnc – Video Journal of Hematology & HemOnc

5 years ago

Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?

Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?

Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?
3:18
Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?
by VJHemOnc – Video Journal of Hematology \& HemOnc
Benedikt Kessler: Proteomics and Biomarkers
8:33
Benedikt Kessler: Proteomics and Biomarkers
by Nuffield Department of Medicine
The CLL2-BZAG trial: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in R\/R CLL
1:11
The CLL2-BZAG trial: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in R\/R CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
HDAC Inhibitors Antineoplastic Drugs for Cancer
1:27
HDAC Inhibitors Antineoplastic Drugs for Cancer
by Drugs in Motion
Immune Checkpoint Inhibitors Antineoplastic Drugs for Cancer
1:24
Immune Checkpoint Inhibitors Antineoplastic Drugs for Cancer
by Drugs in Motion
mTOR Inhibitors Antineoplastic Drugs for Cancer
1:01
mTOR Inhibitors Antineoplastic Drugs for Cancer
by Drugs in Motion
Topoisomerase Inhibitors Antineoplastic Drugs for Cancer
1:30
Topoisomerase Inhibitors Antineoplastic Drugs for Cancer
by Drugs in Motion
PARP Inhibitors Antineoplastic Drugs for Cancer
1:04
PARP Inhibitors Antineoplastic Drugs for Cancer
by Drugs in Motion
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
1:31
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
by VJOncology
A Phase II protocol for a safe combination of chemotherapy for patients with BPDCN
1:23
A Phase II protocol for a safe combination of chemotherapy for patients with BPDCN
by VJHemOnc – Video Journal of Hematology \& HemOnc
Aromatase Inhibitors Antineoplastic Drug for Cancer
1:12
Aromatase Inhibitors Antineoplastic Drug for Cancer
by Drugs in Motion
Sasanlimab BCG combo improves outcomes in high-risk NMIBC
3:49
Sasanlimab BCG combo improves outcomes in high-risk NMIBC
by ecancer
Inhibitors of lymphocyte signaling immunomodulatory agents; Examples of drugs and action
3:31
Inhibitors of lymphocyte signaling immunomodulatory agents; Examples of drugs and action
by MBBS NAIJA
PARP inhibitors in combination with NHAs (SHORT)
6:00
PARP inhibitors in combination with NHAs (SHORT)
by COR2ED The Heart of Medical Education
Efficacy and safety of sonrotoclax in B-cell malignancies
3:30
Efficacy and safety of sonrotoclax in B-cell malignancies
by VJHemOnc – Video Journal of Hematology \& HemOnc
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC
1:52
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC
by ecancer
Types of immunomodulators; agents that modify the immune system’s activity
3:43
Types of immunomodulators; agents that modify the immune system’s activity
by MBBS NAIJA
Introduction to Drug and the Immune System; central to the field of immunopharmacology
3:16
Introduction to Drug and the Immune System; central to the field of immunopharmacology
by MBBS NAIJA
Types of Immune System Modulators or immunomodulators drugs or Agents
3:15
Types of Immune System Modulators or immunomodulators drugs or Agents
by MBBS NAIJA